Literature DB >> 11377299

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.

W W Roberts1, E J Bergstralh, M L Blute, J M Slezak, M Carducci, M Han, J I Epstein, M A Eisenberger, P C Walsh, A W Partin.   

Abstract

OBJECTIVES: To develop a model that will identify a contemporary cohort of patients at high risk of early prostate cancer recurrence (greater than 50% at 36 months) after radical retropubic prostatectomy for clinically localized disease. Data from this model will provide important information for patient selection and the design of prospective randomized trials of adjuvant therapies.
METHODS: Proportional hazards regression analysis was applied to two patient cohorts to develop and cross-validate a multifactorial predictive model to identify men with the highest risk of early prostate cancer recurrence. The model and validation cohorts contained 904 and 901 men, respectively, who underwent radical retropubic prostatectomy at Johns Hopkins Hospital. This model was then externally validated using a cohort of patients from the Mayo Clinic.
RESULTS: A model for weighted risk of recurrence was developed: R(W)'=lymph node involvement (0/1)x1.43+surgical margin status (0/1)x1.15+modified Gleason score (0 to 4)x0.71+seminal vesicle involvement (0/1)x0.51. Men with an R(W)' greater than 2.84 (9%) demonstrated a 50% biochemical recurrence rate (prostrate-specific antigen level greater than 0.2 ng/mL) at 3 years and thus were placed in the high-risk group. Kaplan-Meier analyses of biochemical recurrence-free survival demonstrated rapid deviation of the curves based on the R(W)'. This model was cross-validated in the second group of patients and performed with similar results. Furthermore, similar trends were apparent when the model was externally validated on patients treated at the Mayo Clinic.
CONCLUSIONS: We have developed a multivariate Cox proportional hazards model that successfully stratifies patients on the basis of their risk of early prostate cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377299     DOI: 10.1016/s0090-4295(01)00978-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

1.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

2.  Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

3.  A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy.

Authors:  Mario A Eisenberger
Journal:  Rev Urol       Date:  2003

4.  A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy.

Authors:  Mario A Eisenberger
Journal:  Rev Urol       Date:  2003

5.  Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.

Authors:  Daniel M Moreira; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Leon L Sun; Judd W Moul; Stephen J Freedland
Journal:  Int J Urol       Date:  2010-09-30       Impact factor: 3.369

6.  Effect of DNA methylation on identification of aggressive prostate cancer.

Authors:  Joshi J Alumkal; Zhe Zhang; Elizabeth B Humphreys; Christina Bennett; Leslie A Mangold; Michael A Carducci; Alan W Partin; Elizabeth Garrett-Mayer; Angelo M DeMarzo; James G Herman
Journal:  Urology       Date:  2008-04-02       Impact factor: 2.649

7.  Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.

Authors:  Ziling Huang; Long Zhang; Xianghua Yi; Xiaoting Yu
Journal:  Tumour Biol       Date:  2015-10-24

8.  Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer.

Authors:  Ahmad Ameri; Asdollah Alidoosti; Seyed Yousef Hosseini; Mohammad Parvin; Mohammad Hasan Emranpour; Farnaz Taslimi; Eisa Salehi; Pedram Fadavip
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

9.  Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.

Authors:  Donkena Krishna Vanaja; Mathias Ehrich; Dirk Van den Boom; John C Cheville; R Jeffrey Karnes; Donald J Tindall; Charles R Cantor; Charles Y F Young
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

10.  Circulatory miR-628-5p is downregulated in prostate cancer patients.

Authors:  Anvesha Srivastava; Helle Goldberger; Alexander Dimtchev; Catalin Marian; Offie Soldin; Xin Li; Sean P Collins; Simeng Suy; Deepak Kumar
Journal:  Tumour Biol       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.